Free Trial
NASDAQ:CDT

Conduit Pharmaceuticals 3/28/2025 Earnings Report

Conduit Pharmaceuticals logo
$3.71 +0.23 (+6.61%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.84 +0.13 (+3.50%)
As of 05/27/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Conduit Pharmaceuticals EPS Results

Actual EPS
-$304.95
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Conduit Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conduit Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conduit Pharmaceuticals Earnings Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Conduit Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Conduit Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Conduit Pharmaceuticals and other key companies, straight to your email.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals (NASDAQ:CDT), a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View Conduit Pharmaceuticals Profile

More Earnings Resources from MarketBeat